Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
11 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
AUGUSTINE THERAPEUTICS from Leuven, company number BE0722705230, closed financial year 2025 with a result of € -14.8 million after tax. For that financial year AUGUSTINE THERAPEUTICS recorded a gross margin of € -1.7 million and equity of € 29 million. Compared with financial year 2024, the result moved from € -8.6 million to € -14.8 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 5, 2026.
€ 29 million
▲ € 22.2 million vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -14.8 million
▼ 73 % more loss than in 2024
Profit after tax over the fiscal year.
€ 656,414
▼ 92% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -23.4 million.
People and assets in 2025
11
▲ 5.6 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.6 million
▲ 92% vs 2024
€ 141,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 360,698
▲ € 279,412 vs 2024
Of which on lease € 257,280.
Debts at end 2025
€ 257,120
€ 84,767 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 1.3 million
▼ 25% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 397,954
▲ 30% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -1,985,373 | € -515,794 | € -1,744,519 | € -1,656,750 | ▲ € 87,769 |
| Profit after taxes | € -3,129,266 | € -4,160,747 | € -8,561,799 | € -14,788,759 | ▼ € 6.2 million |
| Equity | € 1,973,293 | € -2,187,454 | € 6,767,866 | € 28,979,107 | ▲ € 22.2 million |
| Total debts | € 733,007 | € 7,493,627 | € 2,050,937 | € 1,928,481 | ▼ 6% |
| Cash | € 1,581,063 | € 3,807,463 | € 7,751,051 | € 656,414 | ▼ 92% |
| Retained profit | € -6,262,053 | € -10,422,800 | € -8,561,799 | € -23,350,558 | ▼ € 14.8 million |
| Bank debt | € 0 | € 5,445,170 | € 0 | € 257,120 | |
| Balance sheet total | € 2,706,300 | € 5,306,173 | € 8,818,803 | € 30,907,588 | ▲ 250% |
| Employees (FTE) | - | - | 5.4 | 11 | ▲ 5.6 |
Key figures of AUGUSTINE THERAPEUTICS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to AUGUSTINE THERAPEUTICS?
What happened at AUGUSTINE THERAPEUTICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Participatiemaatschappij Vlaanderen (PMV) stepped down as director. NBB
- Gerhard Koenig stepped down as director. NBB
- Pascale Florence Geneviève Witz stepped down as director. NBB
- Emmanuelle Coutanceau stepped down as director. NBB
- Mahieddine El Mahdi Ainouche stepped down as director. NBB
- Clara Campàs Moya stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 14.8 million. Source: NBB ↗
- Pascale Florence Geneviève Witz became a director. NBB
In short
From € 3.1 million loss in 2022 to € 14.8 million loss in 2025.
A new publication or filing at AUGUSTINE THERAPEUTICS? We notify you, reason included.
Follow AUGUSTINE THERAPEUTICSDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY, V-Bio Fund 1, Participatiemaatschappij Vlaanderen, BIOTECH FONDS VLAANDEREN, Newton Biocapital II comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
AUGUSTINE THERAPEUTICSThe shares are held by VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY (10.5%), V-Bio Fund 1 (10.1%), Participatiemaatschappij Vlaanderen (8.6%), BIOTECH FONDS VLAANDEREN (3.8%) and Newton Biocapital II (3.3%). It owns 100% of Augustine Therapeutics Denmark ApS itself.
Directors
According to the 2025 annual accounts
Participatiemaatschappij Vlaanderen (PMV)
Director · represented by Bart De Taeye
Also active at: VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK, Arts Gebroeders immobilière, BEDRIJVENCENTRUM VILVOORDE, BIOTECH FONDS VLAANDEREN, MAISON DE LA RADIO FLAGEY, HERTECANT FLANGES, Site-Ontwikkeling Vlaanderen, SUSTAINABLE ENERGY VENTURES +136 more
since 2025 · until 2031
Gerhard Koenig
Director
since 2025 · until 2031
Alain Huriez
Director
since 2024 · until 2025
Pascale Florence Geneviève Witz
Director
since 2025 · until 2031
Emmanuelle Coutanceau
Director
since 2025 · until 2031
Ward Capoen
Director
since 2024 · until 2025
Mahieddine El Mahdi Ainouche
Director
since 2025 · until 2031
Sylvain Celanire
Managing director
since 2024 · until 2025
Clara Campàs Moya
Director
since 2025 · until 2031
Shareholders
Participations
Augustine Therapeutics Denmark ApS
100%
Establishments
Establishment units
Physical locations of this company
Gaston Geenslaan 3
3001 Leuven
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 11 companies are registered at this address.
All companies at this address →QUOMAK
€ 4.6 million gross margin · 2025
Metaptys
€ 1.3 million gross margin · 2025
Perseus Biomics
€ 320,026 gross margin · 2025
ReWind Therapeutics same network
€ -528,262 gross margin · 2025
Montis Biosciences
€ -2.1 million gross margin · 2025
+6 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
CLOUDFLARESPECTRUM Cloudflare, Inc., US
Domain
Domain
augustinetx.com
Registered
2019-12-12
Registrar
Combell NV
Expires
2026-12-12
Website info
Features
Security
Details
- Company number
- 0722.705.230
- VAT number
- BE 0722.705.230
- Registered office
- Gaston Geenslaan 3, 3001 Leuven
- Names & denominations
- AUGUSTINE THERAPEUTICS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 13 March 2019
- Peppol
- Active · Active since 1 Dec 2025
- Contact
- augustinetx.com
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied